Cannara Biotech posts 254% increase in EBITDA in 2022

Cannara Biotech posts 254% increase in EBITDA in 2022

A 254% increase in EBITDA for fiscal year 2022 was due to the increase in positive adjusted EBITDA to CA $5.3 million, a 254% increase compared to fiscal year 2021.

This past year was a great success, and I am very proud of the team at Cannara for their dedication, hard work and support as we continue to strive to be one of the leading cannabis cultivators in the country, said Zohar Krivorot, president and CEO of Cannara. As of today, seven of its twenty-four growing zones, each of which contain 9,600 plants, are producing. Krivorot said that they remain confident in fulfilling the remaining grow zones over the coming quarters, and that our successful harvests should shed any doubt regarding our ability to achieve all of our expansion milestones and bring more premium-grade cannabis to market.

You can get a daily dose of cannabis news on Benzinga Cannabis. Cannara Biotech enters the British Columbia Cannabis Market and launches new products.

Cannara Biotech Signs An Exclusive Brand Partnership With Exotic Genetix In Canada

Cannara Biotech Revenue Grows 41% YoY, Here Are The Details